Allogene Therapeutics: Q3 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $61.3 million in its third quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 37 cents.
The results exceeded Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 53 cents per share.
The immuno-oncology company posted revenue of $43,000 in the period, matching Street forecasts.
In the final minutes of trading on Thursday, the company's shares hit $2.98. A year ago, they were trading at $10.17.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO
